Abstract:Osteosarcoma (OS) stands as the most common type of primary malignant bone tumor. Its incidence demonstrates a bimodal distribution, with peaks typically occurring at 18 and 60 years of age, with a slight male predilection towards OS development. [ 1 ] OS is recognized for its intricate heterogeneity and the abnormal production of immature osteoid matrix, [ 2–4 ] rendering it the prevalent malignant bone-related cancer among young individuals. Current treatment modalities for OS encompass neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. [ 5 , 6 ] Despite concerted efforts by researchers, there has been negligible progress in improving the 5-year survival rate of OS patients over recent decades, underscoring the inadequacy of current therapeutic approaches. [ 7–9 ] Moreover, these methods often fall short in effectively eradicating all OS cells due to challenges in drug delivery precision, particularly concerning metastatic and circulating OS cells, thus predisposing to tumor recurrence and progression. [ 10 , 11 ] Hence, there is an urgent imperative to explore innovative therapeutic strategies for OS. Furthermore, acquired drug resistance commonly manifests in OS patients, concomitant with metastasis or recurrence in distant organs. The overall 5-year cumulative survival rate remains dismally low at 20%, with a persistently high recurrence rate of approximately 35%. [ 12 ]

Network pharmacology, molecular docking, and molecular dynamics simulations shed light on the mechanism behind Gynostemma pentaphyllum's efficacy against osteosarcoma